These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 19075129

  • 1. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer.
    Lee DW, Anderson ME, Wu S, Lee JH.
    Arch Otolaryngol Head Neck Surg; 2008 Dec; 134(12):1316-23. PubMed ID: 19075129
    [Abstract] [Full Text] [Related]

  • 2. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH.
    Clin Cancer Res; 2008 Jan 01; 14(1):178-87. PubMed ID: 18172269
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
    Kim TY, Myoung HJ, Kim JH, Moon IS, Kim TG, Ahn WS, Sin JI.
    Cancer Res; 2002 Dec 15; 62(24):7234-40. PubMed ID: 12499264
    [Abstract] [Full Text] [Related]

  • 5. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
    Huang CY, Chen CA, Lee CN, Chang MC, Su YN, Lin YC, Hsieh CY, Cheng WF.
    Gynecol Oncol; 2007 Dec 15; 107(3):404-12. PubMed ID: 17905417
    [Abstract] [Full Text] [Related]

  • 6. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
    Albers A, Abe K, Hunt J, Wang J, Lopez-Albaitero A, Schaefer C, Gooding W, Whiteside TL, Ferrone S, DeLeo A, Ferris RL.
    Cancer Res; 2005 Dec 01; 65(23):11146-55. PubMed ID: 16322265
    [Abstract] [Full Text] [Related]

  • 7. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine.
    Sewell DA, Douven D, Pan ZK, Rodriguez A, Paterson Y.
    Arch Otolaryngol Head Neck Surg; 2004 Jan 01; 130(1):92-7. PubMed ID: 14732776
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.
    Daemen T, Regts J, Holtrop M, Wilschut J.
    Gene Ther; 2002 Jan 01; 9(2):85-94. PubMed ID: 11857066
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice.
    Riezebos-Brilman A, Regts J, Freyschmidt EJ, Dontje B, Wilschut J, Daemen T.
    Gene Ther; 2005 Sep 01; 12(18):1410-4. PubMed ID: 15843807
    [Abstract] [Full Text] [Related]

  • 13. Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model.
    Qian X, Lu Y, Liu Q, Chen K, Zhao Q, Song J.
    Immunol Lett; 2006 Feb 15; 102(2):191-201. PubMed ID: 16242781
    [Abstract] [Full Text] [Related]

  • 14. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
    Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, van der Burg SH, Melief CJ.
    Clin Cancer Res; 2008 Jan 01; 14(1):169-77. PubMed ID: 18172268
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
    Baldwin PJ, van der Burg SH, Boswell CM, Offringa R, Hickling JK, Dobson J, Roberts JS, Latimer JA, Moseley RP, Coleman N, Stanley MA, Sterling JC.
    Clin Cancer Res; 2003 Nov 01; 9(14):5205-13. PubMed ID: 14614000
    [Abstract] [Full Text] [Related]

  • 17. Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies.
    Peng S, Trimble C, Ji H, He L, Tsai YC, Macaes B, Hung CF, Wu TC.
    J Biomed Sci; 2005 Oct 01; 12(5):689-700. PubMed ID: 16200349
    [Abstract] [Full Text] [Related]

  • 18. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
    Ohlschläger P, Pes M, Osen W, Dürst M, Schneider A, Gissmann L, Kaufmann AM.
    Vaccine; 2006 Apr 05; 24(15):2880-93. PubMed ID: 16472545
    [Abstract] [Full Text] [Related]

  • 19. Dissimilar immunogenicities of human papillomavirus E7 and adenovirus E1A proteins influence primary tumor development.
    Routes JM, Ryan S, Li H, Steinke J, Cook JL.
    Virology; 2000 Nov 10; 277(1):48-57. PubMed ID: 11062035
    [Abstract] [Full Text] [Related]

  • 20. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
    Daemen T, Pries F, Bungener L, Kraak M, Regts J, Wilschut J.
    Gene Ther; 2000 Nov 10; 7(21):1859-66. PubMed ID: 11110419
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.